The effect of hypothyroidism on referential background metabolic activity on 18F-FDG PET/CT
Original Article

The effect of hypothyroidism on referential background metabolic activity on 18F-FDG PET/CT

Pei Yang#, Qiuping Fan#, Huawei Cai, Rong Tian, Minggang Su

Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, China

#These authors contributed equally to this work.

Correspondence to: Minggang Su, MD. Department of Nuclear Medicine, West China Hospital, Sichuan University, 37 Guoxue Alley, Chengdu 610041, China. Email: suminggang@sina.com.

Background: Background uptake activity is used as a reference to assess treatment response by positron emission tomography-computed tomography (PET/CT) with 2-deoxy-2-[F-18]fluoro- D-glucose (18F-FDG). Prior studies have reported decreased liver and increased muscle 18F-FDG uptake in patients with hyperthyroidism. We hypothesized that hyperthyroidism and hypothyroidism might have inverse effects on 18F-FDG uptake on PET/CT.

Methods: We recruited 36 patients with hypothyroidism and 36 age and gender-matched euthyroid participants. We recorded patient factors and background mean standardized uptake values normalized by lean body mass from the aortic blood pool, liver, and muscle. We compared the patient factors and background standardized uptake values normalized by lean body mass between hypothyroidism patients and the controls. We performed a multivariate analysis to determine the best predictors of the 3 different background standardized uptake values normalized by lean body mass.

Results: Patients with hypothyroidism had higher liver standardized uptake values normalized by lean body mass (1.77±0.33 vs. 1.58±0.26, P=0.009) and aortic blood-pool standardized uptake values normalized by lean body mass (1.21±0.22 vs. 1.11±0.20, P=0.040) than the controls. In contrast, the muscle standardized uptake value normalized by lean body mass (0.50±0.09 vs. 0.54±0.09, P=0.044) of the patients with hypothyroidism was lower than that of the controls. The serum level of thyroid-stimulating hormone was an independent predictor of liver standardized uptake values normalized by lean body mass (β=0.356, P<0.001) and blood-pool standardized uptake values normalized by lean body mass (β=0.288, P=0.001). The serum level of free triiodothyronine was an independent predictor of muscle standardized uptake values normalized by lean body mass (β=0.310, P=0.002).

Conclusions: PET/CT scans showed that hypothyroidism patients had increased liver and blood-pool 18F-FDG uptake and decreased skeletal muscle 18F-FDG uptake compared with euthyroid individuals. These alterations should be noted when a metabolic response to cancer treatment on PET/CT is determined.

Keywords: 2-deoxy-2-[F-18]fluoro-D-glucose (18F-FDG); positron emission tomography-computed tomography (PET/CT); liver; blood pool; hypothyroidism


Submitted Nov 27, 2020. Accepted for publication Apr 01, 2021.

doi: 10.21037/qims-20-1310


Introduction

Positron emission tomography-computed tomography (PET/CT) with 2-deoxy-2-[F-18]fluoro-D-glucose (18F-FDG) is widely used to evaluate responses to cancer treatment. In clinical practice, the standardized uptake value (SUV) of background tissues such as the aortic blood pool and the liver is often used as references for accurate treatment response interpretation (1-3). However, variations in biological factors such as blood glucose level and incubation time (time from FDG injection to PET/CT scan) can affect the 18F-FDG uptake in these regions (4-7). This can be problematic when a metabolic response is defined, especially for quantitative evaluation, based on the PET Response Criteria in Solid Tumors (PERCIST). The PERCIST requires that a measurable tumor uptake is determined relative to the activity of a background (1-3).

Prior studies reported that 18F-FDG uptake was decreased in the liver and increased in the muscles of patients with hyperthyroidism, likely due to increased endogenous liver glucose production and increased heat production by the muscles (8-10). Hypothyroidism is much more common than hyperthyroidism, especially in the aging population, in patients treated with certain drugs (lithium, amiodarone, tyrosine kinase inhibitors, immune checkpoint inhibitors, etc.), and in patients that have received neck radiotherapy (11-13). Theoretically, individuals with hypothyroidism should have increased liver glycogenesis but decreased skeletal muscle glucose uptake compared with individuals with normal thyroid function (14). Therefore, we hypothesized that the pattern of 18F-FDG uptake on PET/CT in patients with hypothyroidism would be the inverse of that in hyperthyroidism patients. Hypothyroidism should be noted before 18F-FDG PET/CT is used to evaluate cancer treatment response if the hypothesis is correct. To test our hypothesis, we characterized the referential background 18F-FDG uptakes in patients with hypothyroidism and compared them with those with normal thyroid function.


Methods

This study was approved by the Institutional Review Board of the West China Hospital and was conducted according to the Declaration of Helsinki guidelines. The requirement to obtain written, informed patient consent was waived because the study was retrospective.

Patient selection

A total of 36 patients with hypothyroidism who underwent PET/CT scans from June 2012 to December 2018 and met the following inclusion and exclusion criteria were involved in this retrospective study. The inclusion criteria were as follows: age higher than 18 years, thyroid status confirmed by a laboratory test within 2 days of the PET/CT scan, normal liver and renal function, and normal blood cell count. Individuals with diabetes, a history of chemotherapy, tumor involvement of the aorta, liver, or muscle, history of liver radiotherapy, steatosis, hepatitis, or 18F-FDG extravasation at the injection time were excluded from the study. Hypothyroidism was defined based on a serum thyroid-stimulating hormone (TSH) level higher than 4.20 mU/L and free thyroxine concentrations below the reference range (12.0–22.0 mU/L). All patients had overt iatrogenic hypothyroidism, and 35 patients received total thyroidectomy because of thyroid cancer, and they all withdrew levothyroxine 2–3 weeks before PET/CT scans. The other 1 patient received radioiodine treatment due to Graves’ disease.

Based on the 1:1 age-gender paring rules, we also enrolled 36 control individuals who underwent cancer screening during the same period and were found to be healthy with normal thyroid function. Patients with a serum TSH level from 0.27–4.20 mU/L were considered to have normal thyroid function. Serum TSH was measured using a time-resolved immunofluorometric assay (Anytest; Sym-Bio Lifescience Co. Ltd, Shanghai, China).

PET/CT protocol

All of the participants fasted for at least 6 h before receiving an injection of 18F-FDG (5.55 MBq/kg). The participants’ fasting blood glucose levels were all within the normal range (less than 7.0 mmol/L). An attenuation CT scan was performed using a low-dose (120 kV, 40 mAs, slice thickness 5 mm), a non-contrast protocol for attenuation and localization of abnormal 18F-FDG activity. PET images were acquired from the mid-thigh to the skull base at a speed of 1.5 min per bed and reconstructed using a line-of-response row-action maximum likelihood algorithm. All of the scans were performed using a Gemini GXL PET/CT scanner (Philips, Netherlands).

Measurements of background SUVs

Background mean SUVs from the aortic blood pool, liver, and muscle were recorded. We calculated the aortic blood-pool SUV by drawing 3 circular regions of interest (ROIs) on 3 contiguous slices within the thoracic aorta’s lumen, taking care not to include the vessel wall in the ROIs. We determined the liver SUV manually by placing a volume of interest with a diameter of 3 cm in the center of the right hepatic lobe (15). We determined the muscle SUV by selecting 3 circular ROIs on 3 contiguous slices in the erector spinae at the level of the 12th thoracic vertebra, making sure the ROIs were within the margins of the muscle. We then computed normalized SUVs (SULs) that accounted for lean body mass (LBM) using the following formulas, where BMI is body mass index (kg/m2) (15).

SUL=Ac t VOI (KBq/mL)Ac t administered (MBq)/LBM(kg)

LB M male =9,270×weight/(6,680+216×BIM)

LB M female =9,270×weight/(8,780+244×BIM)

Statistical analysis

Background SULs along with patient factors [age, height, weight, BMI, blood glucose level, LBM, injected 18F-FDG dose, incubation time, accumulated radioiodine dose in patients that received radioiodine treatment, serum TSH levels, free triiodothyronine (FT3) levels, and free thyroxine (FT4) levels)] were recorded. Because of a methodological issue with specimen dilution, we could not accurately measure serum TSH levels higher than 100 mU/L, so we assigned serum TSH levels higher than 100 mU/L a value of 100 mU/L. We used the mean ± standard deviation (SD) for normal variables and the interquartile range P50 (P25, P75) for non-normal variables for descriptive statistics. We evaluated the normality of the data using the Kolmogorov-Smirnov test. We compared the background SULs and patient factors between the patients with hypothyroidism and the controls using the independent sample t-test or Mann-Whitney U-test. Then, we calculated the relative difference in each background SUL between patients with hypothyroidism and the controls. Subsequently, we examined associations between the background SULs and the other patient factors by performing Pearson’s or Spearman’s correlations. Finally, we performed a stepwise multivariate analysis to determine the best predictors of the 3 different background SULs. All statistical analyses were performed using SPSS 20.0 software (SPSS Inc., Chicago, Illinois, USA). P values less than 0.05 were considered statistically significant.


Results

Patient characteristics

A total of 72 participants matched for age and gender (mean age: 44.14±10.35 years; 40 female, 32 male) were included. The SULs and patient factors were distributed normally, except for the TSH, FT3, and FT4 levels, accumulated radioiodine dose, incubation time, and LBM. There were no significant differences between the patients with hypothyroidism and the controls in terms of height, weight, BMI, injected 18F-FDG dose, blood glucose level, incubation time, or LBM. There were significant differences between the 2 groups in TSH, FT3, and FT4 levels (P<0.001 for each factor; Table 1).

Table 1
Table 1 General characteristics of the study participants
Full table

Background SULs

The hypothyroidism patients had higher liver SUL (L-SUL) and blood-pool SUL (BP-SUL) than the controls. The L-SUL was 1.77±0.33 for the hypothyroid group and 1.58±0.26 for the euthyroid group (P=0.009). The BP-SUL was 1.21±0.22 for hypothyroidism patients and 1.11±0.20 for the controls (P=0.040). In contrast, the muscle SUL (M-SUL) was lower in the patients with hypothyroidism (0.50±0.09) than in the controls (0.54±0.09, P=0.044). The detailed results are shown in Table 2, Figures 1,2.

Table 2
Table 2 SULs of the liver, aortic blood pool, and skeletal muscle in the patients and controls
Full table
Figure 1 Comparisons of the liver, aortic blood-pool, and skeletal muscle SULs between patients with hypothyroidism and controls. The circles in the error bars represent the mean SUL of each background, and the bars represent the 95% CI of the SULs of each group. SUL, standard uptake value normalized by lean body mass; L-SUL, liver normalized standard uptake value; BP-SUL, aortic blood-pool normalized standard uptake value; M-SUL, muscle normalized standard uptake value.
Figure 2 Representative PET maximum intensity projection images of a 37-year-old female patient with hypothyroidism (A) and age and gender-matched control individual (B). The 2 subjects were similar in height (162 and 163 cm), weight (50 and 57 kg), BMI (19.1 and 21.5 kg/m2), blood glucose level (5.1 and 4.8 mmol/L), LBM (34.5 and 37.7 kg), injected 18F-FDG dose (290 and 321 MBq), and incubation time (64 and 72 min). The values for serum TSH (100 and 1.25 mU/L), free triiodothyronine (1.27 and 5.17 mU/L), and free thyroxine (2.99 and 13.96 mU/L) were typical for hypothyroid and euthyroid status, respectively. The liver and aortic blood-pool SULs were higher in the patient with hypothyroidism (1.52 and 1.02, respectively) than in the control subject (1.19 and 0.77, respectively). By contrast, the muscle SUL was higher in the control subject (0.44) than in the patient with hypothyroidism (0.41). SUL, standard uptake value normalized by lean body mass; BMI, body mass index; LBM, lean body mass; TSH, serum thyroid-stimulating hormone.

Bivariate correlation analysis of the background SULs and other factors

All of the background SULs were positively correlated with gender, height, and LBM (P<0.01 for each correlation; Table 3). L-SUL and BP-SUL were positively correlated with weight, 18F-FDG dose, and TSH level (P<0.05, for each correlation). Also, M-SUL was positively correlated with the FT3 and FT4 levels (P<0.01 for each correlation). By contrast, BP-SUL was negatively correlated with incubation time (P=0.002). We investigated the correlations between the accumulated radioiodine dose and each background SUL to determine if radioiodine impacted, but we found no correlations with this factor. The correlations between SULs and thyroid function are shown in Figure 3.

Table 3
Table 3 Significant bivariate correlations between background SULs and other patient factors
Full table
Figure 3 The correlations between thyroid function and the SULs on 18F-FDG PET/CT by Spearman’s rank analysis. L-SUL (A) and BP-SUL (B) directly correlated with TSH levels (rho =0.302 and 0.299, both P<0.05). (C) M-SUL directly correlated with FT3 levels (rho =0.376, P<0.05). SUL, standard uptake value normalized by lean body mass; TSH, serum thyroid-stimulating hormone; FT3, serum free triiodothyronine; FT4, serum free thyroxine; L-SUL, liver normalized standard uptake value; BP-SUL, aortic blood-pool normalized standard uptake value, M-SUL, muscle normalized standard uptake value.

As muscle activity, and therefore muscle 18F-FDG uptake may be partly dependent on muscular heat production, we took seasonal influences and the outside temperature on the scanning day into account. We found that the M-SUL was not correlated with the season and outside max/min temperature. The detailed results are shown in Tables S1,S2.

Multivariate linear regression of the background SULs and other patient factors

After adjusting for all other significant factors that included gender, height, weight, 18F-FDG dose, LBM, incubation time, TSH, FT3, and FT4 in the bivariate correlations using a stepwise multivariate analysis, we found that the TSH level was an independent predictor of L-SUL (β=0.356, P<0.001) and BP-SUL (β=0.288, P=0.001). In addition, we found that the FT3 level was an independent predictor of M-SUL (β=0.310, P=0.002; Table 4).

Table 4
Table 4 Independent predictors of background SULs in the multivariate analysis
Full table

Discussion

It is common in clinical practice to use PET/CT with background activity as a reference to assess the treatment response of lymphoma or solid cancers. A complete metabolic response (CMR) is determined if the lesion’s residual activity is equal to or lower than that of the liver or blood pool (1-3). Accurate evaluation of the treatment response is important for prognosis prediction and for making decisions about the therapeutic strategy (2,16). Both require a stable background activity, which is susceptible to many biological factors (4-6). Therefore, various factors must be checked before PET/CT results are used to interpret a treatment response. Prior studies reported the effects of hyperthyroidism on liver and muscle 18F-FDG uptake (8-10). However, there is little information about the effects of hypothyroidism on background 18F-FDG uptake. We found that patients with overt hypothyroidism had higher L-SUL and BP-SUL and lower M-SUL than individuals with normal thyroid function. These variations in background activity should not be ignored in the interpretations of PET/CT images.

We found that the serum TSH level was an independent predictor of L-SUL. Although TSH might not directly impact liver glucose metabolism, it might have an indirect influence through its effects on other target organs. The TSH receptor (TSHR) is expressed in pancreatic islets, where its activation enhances insulin secretion from β-cells (17). Insulin can increase cell permeability and stimulate the catalytic actions of enzymes such as glucokinase, glycogen synthetase, and phosphofructokinase in the liver, which in turn increase the rates of glycogen formation and glycolysis in the liver (18-20). Additionally, Lyu et al. showed that TSH increases the level of glucokinase in pancreatic islet β-cells and directly affects glucose uptake in these cells by upregulating the expression of glucose transporter 2 (GLUT-2) (17). Similar to pancreatic islet β-cells, hepatocytes also express TSHR, GLUT-2, and glucokinase (17,21-23). Therefore, the same biochemical process observed in pancreatic islet β-cells might also occur in hepatocytes, which would explain the observed relationship between TSH and L-SUL in our study. Finally, the liver SUL is typically determined by its contained un-phosphorylated 18F-FDG and its 18F-FDG-6-phosphate. The former reflects blood FDG concentration. We also found a strong positive correlation between L-SUL and BP-SUL. Thus, the elevated BP-SUL may also partially explain the elevated L-SUL.

There are several potential explanations behind the finding of the positive impact of TSH on BP-SUL. At the cellular level, TSHR is found in erythrocytes, lymphocytes, and granulocytes of the peripheral blood, which might influence metabolic activity (21,24). TSH enhances insulin secretion, which stimulates glucose absorption mediated by sodium-glucose cotransporter 2 in the renal proximal tubules (25,26). As a glucose analog, 18F-FDG is transported into the cells and gets trapped there after phosphorylation. In the presence of glucose-6-phosphatase, the phosphorylated 18F-FDG can be dephosphorylated and released back into the blood (27). At the tissue level, glucose-6-phosphatase is expressed mainly in the liver, where phosphorylated 18F-FDG can be dephosphorylated (28). Therefore, there is a dynamic equilibration between the liver accumulation of 18F-FDG and free 18F-FDG in the blood pool.

It has been reported that muscle glucose homeostasis and energy expenditure require the binding of T3 to thyroid hormone nuclear receptors (29). Hypothyroidism lowers the rate of ATP hydrolysis from muscle glucose metabolism, resulting in decreased heat production by the muscles (30). In individuals with normal thyroid function or hyperthyroidism, insulin promotes the trafficking of GLUT-4 from storage vesicles to the plasma membrane, thus facilitating glucose uptake from the circulation (18,31,32). The expression of GLUT­4 in muscle cells is T3 dependent; however, individuals with hypothyroidism are expected to have reduced GLUT­4 expression due to decreased levels of serum T3 (29). Also, the reduced rate of glycolysis caused by hypothyroidism can result in a decrease in the rate of insulin-stimulated glucose utilization (31). For these reasons, glucose uptake is expected to be lower in patients with hypothyroidism than in patients with normal thyroid function or hyperthyroidism. Our results are in line with those of Chen et al., who investigated 18F-FDG uptake in patients with hyperthyroidism and found a positive correlation between the serum T3 level and muscle 18F-FDG uptake (8).

Adequate repeatability and reproducibility are essential for the evaluation of metabolic response following treatment. It is easy to use the same image acquisition and the same reconstruction parameters on patients with serial examinations or on patients treated with different regimes. However, it is difficult to maintain certain physiological conditions, such as thyroid function, across different time points or multiple patients. Our results suggest that patients with overt hypothyroidism are more prone to false CMR interpretation than patients with normal thyroid function because of the metabolic response criteria and the increased liver and blood-pool activities associated with overt hypothyroidism (1-3). Hence, knowledge of the impact of thyroid function on background activities is important for accurate response interpretation and for response comparisons among different therapeutic regimes.

The main limitation of our study was the relatively small sample size. The patients we selected all had severe iatrogenic hypothyroidism due to total thyroidectomy or radioiodine therapy, which might increase the statistical bias, and the results of our study may not be generalizable to mild hypothyroidism. Furthermore, we did not analyze whether tumor burden was one of the impact factors for the SULs in the overt hypothyroidism group. Viglianti et al. demonstrated that tumor burden harms these sites’ FDG uptake due to the FDG reservoir or sink effect (33). According to this, much higher liver and blood-pool activities could be expected in the hypothyroid patient if there was no FDG avid tumor. Unlike in the prior study, none of the participants had multiple 18F-FDG PET/CT scans taken at times when their thyroid status was different, so it was not possible to make intrapatient comparisons between hypothyroid and euthyroid statuses (8). Also, we could not accurately measure serum TSH values higher than 100 mU/L because of a methodological issue, which might have affected our determination of the best predictors of different background SULs.

Despite the limitations, our results still indicated that overt hypothyroidism increased liver and blood-pool 18F-FDG uptake and decreased skeletal muscle 18F-FDG uptake compared with euthyroid individuals. We believe that overt abnormal thyroid function should be cured in patients who require metabolic response evaluation by 18F-FDG PET/CT. The possibility of false-positive/false-negative results should be taken into account for those who cannot recover thyroid function completely. Because the influence of thyroid function on glucose metabolism is systemic, it may also affect other organs. Whether there is a more suitable background region requires further study. Additionally, recombinant human TSH injection before 18F-FDG PET/CT may have a similar effect, although thyroid hormone levels are not significantly changed. Finally, for further validation of our results, studies with larger sample sizes will be required, and diverse hypothyroidism levels should be included.


Conclusions

PET/CT scans showed a pattern of increased 18F-FDG uptake in the liver and blood pool and decreased 18F-FDG uptake in the skeletal muscle in patients with hypothyroidism. The magnitude of the alterations in 18F-FDG uptake corresponded to the severity of the hypothyroidism. Overt abnormal thyroid function should be noted before PET/CT is used to determine a cancer treatment’s metabolic response.


Acknowledgments

Funding: This work was supported by the Sichuan Provincial Department of Science and Technology support program (2015SZ0128) and National Key Research and Development Program of China during the “13th Five-year Plan” (2016YFC0104300).


Footnote

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/qims-20-1310). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. This study was approved by the Institutional Review Board of the West China Hospital and was conducted according to the Declaration of Helsinki guidelines (as revised in 2013). The requirement to obtain written, informed patient consent was waived because the study was retrospective.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.


References

  1. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med 2009;50:122s-50s. [Crossref] [PubMed]
  2. Marcus C, Ciarallo A, Tahari AK, Mena E, Koch W, Wahl RL, Kiess AP, Kang H, Subramaniam RM. Head and neck PET/CT: therapy response interpretation criteria (Hopkins Criteria)-interreader reliability, accuracy, and survival outcomes. J Nucl Med 2014;55:1411-6. [Crossref] [PubMed]
  3. Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Mueller SP, Schwartz LH, Zucca E, Fisher RI, Trotman J, Hoekstra OS, Hicks RJ, O’Doherty MJ, Hustinx R, Biggi A, Cheson BD. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol 2014;32:3048-58. [Crossref] [PubMed]
  4. Adams MC, Turkington TG, Wilson JM, Wong TZ. A systematic review of the factors affecting accuracy of SUV measurements. AJR Am J Roentgenol 2010;195:310-20. [Crossref] [PubMed]
  5. Chiaravalloti A, Danieli R, Abbatiello P, Di Pietro B, Travascio L, Cantonetti M, Guazzaroni M, Orlacchio A, Simonetti G, Schillaci O. Factors affecting intrapatient liver and mediastinal blood pool 18F-FDG standardized uptake value changes during ABVD chemotherapy in Hodgkin’s lymphoma. Eur J Nucl Med Mol Imaging 2014;41:1123-32. [Crossref] [PubMed]
  6. Ceriani L, Suriano S, Ruberto T, Zucca E, Giovanella L. 18F-FDG uptake changes in liver and mediastinum during chemotherapy in patients with diffuse large B-cell lymphoma. Clin Nucl Med 2012;37:949-52. [Crossref] [PubMed]
  7. Cao Y, Zhou K, Diao W, Long X, Tian F, Su M, Jia Z. Age-related changes of standardized uptake values in the blood pool and liver: a decade-long retrospective study of the outcomes of 2,526 subjects. Quant Imaging Med Surg 2021;11:95-106. [Crossref] [PubMed]
  8. Chen YK, Chen YL, Tsui CC, Wang SC, Cheng RH. The significance of alteration 2-[fluorine-18]fluoro-2-deoxy-(D)-glucose uptake in the liver and skeletal muscles of patients with hyperthyroidism. Acad Radiol 2013;20:1218-23. [Crossref] [PubMed]
  9. Kim MH, Kim DW, Park SA, Kim CG. Transiently Altered Distribution of F-18 FDG in a Patient with Subacute Thyroiditis. Nucl Med Mol Imaging 2018;52:82-4. [Crossref] [PubMed]
  10. Chen YK, Wang YF, Chiu JS. Diagnostic trinity: Graves’ disease on F-18 FDG PET. Clin Nucl Med 2007;32:816-7. [Crossref] [PubMed]
  11. Taylor PN, Albrecht D, Scholz A, Gutierrez-Buey G, Lazarus JH, Dayan CM, Okosieme OE. Global epidemiology of hyperthyroidism and hypothyroidism. Nat Rev Endocrinol 2018;14:301-16. [Crossref] [PubMed]
  12. Chaker L, Bianco AC, Jonklaas J, Peeters RP. Hypothyroidism. Lancet 2017;390:1550-62. [Crossref] [PubMed]
  13. Pil J, Nevens D, Van der Vorst A, Gadan C, Nuyts S. The incidence of hypothyroidism after radiotherapy for head and neck cancer. B-ENT 2016;12:257-62. [PubMed]
  14. Mullur R, Liu YY, Brent GA. Thyroid hormone regulation of metabolism. Physiol Rev 2014;94:355-82. [Crossref] [PubMed]
  15. Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, Verzijlbergen FJ, Barrington SF, Pike LC, Weber WA, Stroobants S, Delbeke D, Donohoe KJ, Holbrook S, Graham MM, Testanera G, Hoekstra OS, Zijlstra J, Visser E, Hoekstra CJ, Pruim J, Willemsen A, Arends B, Kotzerke J, Bockisch A, Beyer T, Chiti A, Krause BJ. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging 2015;42:328-54. [Crossref] [PubMed]
  16. Barrington SF, Johnson PWM. (18)F-FDG PET/CT in Lymphoma: Has Imaging-Directed Personalized Medicine Become a Reality? J Nucl Med 2017;58:1539-44. [Crossref] [PubMed]
  17. Lyu J, Imachi H, Yoshimoto T, Fukunaga K, Sato S, Ibata T, Kobayashi T, Dong T, Yonezaki K, Yamaji N, Kikuchi F, Iwama H, Ishikawa R, Haba R, Sugiyama Y, Zhang H, Murao K. Thyroid stimulating hormone stimulates the expression of glucose transporter 2 via its receptor in pancreatic beta cell line, INS-1 cells. Sci Rep 2018;8:1986. [Crossref] [PubMed]
  18. Petersen MC, Shulman GI. Mechanisms of Insulin Action and Insulin Resistance. Physiol Rev 2018;98:2133-223. [Crossref] [PubMed]
  19. Lenzen S. A fresh view of glycolysis and glucokinase regulation: history and current status. J Biol Chem 2014;289:12189-94. [Crossref] [PubMed]
  20. Ramnanan CJ, Edgerton DS, Rivera N, Irimia-Dominguez J, Farmer B, Neal DW, Lautz M, Donahue EP, Meyer CM, Roach PJ, Cherrington AD. Molecular characterization of insulin-mediated suppression of hepatic glucose production in vivo. Diabetes 2010;59:1302-11. [Crossref] [PubMed]
  21. Williams GR. Extrathyroidal expression of TSH receptor. Ann Endocrinol (Paris) 2011;72:68-73. [Crossref] [PubMed]
  22. Thorens B. GLUT2, glucose sensing and glucose homeostasis. Diabetologia 2015;58:221-32. [Crossref] [PubMed]
  23. Matschinsky FM. Glucokinase as glucose sensor and metabolic signal generator in pancreatic beta-cells and hepatocytes. Diabetes 1990;39:647-52. [Crossref] [PubMed]
  24. Balazs C, Bokk A, Kiss E. Inhibition of metabolic activity of polymorphonuclear granulocytes by thyroid stimulating antibodies. J Endocrinol Invest 1992;15:465-9. [Crossref] [PubMed]
  25. Nakamura N, Matsui T, Ishibashi Y, Yamagishi S. Insulin stimulates SGLT2-mediated tubular glucose absorption via oxidative stress generation. Diabetol Metab Syndr 2015;7:48. [Crossref] [PubMed]
  26. Singh S, Sharma R, Kumari M, Tiwari S. Insulin receptors in the kidneys in health and disease. World J Nephrol 2019;8:11-22. [Crossref] [PubMed]
  27. Maschauer S, Prante O, Hoffmann M, Deichen JT, Kuwert T. Characterization of 18F-FDG uptake in human endothelial cells in vitro. J Nucl Med 2004;45:455-60. [PubMed]
  28. van Schaftingen E, Gerin I. The glucose-6-phosphatase system. Biochem J 2002;362:513-32. [Crossref] [PubMed]
  29. Salvatore D, Simonides WS, Dentice M, Zavacki AM, Larsen PR. Thyroid hormones and skeletal muscle--new insights and potential implications. Nat Rev Endocrinol 2014;10:206-14. [Crossref] [PubMed]
  30. Leijendekker WJ, van Hardeveld C, Elzinga G. Heat production during contraction in skeletal muscle of hypothyroid mice. Am J Physiol 1987;253:E214-20. [PubMed]
  31. Dimitriadis G, Parry-Billings M, Bevan S, Leighton B, Krause U, Piva T, Tegos K, Challiss RA, Wegener G, Newsholme EA. The effects of insulin on transport and metabolism of glucose in skeletal muscle from hyperthyroid and hypothyroid rats. Eur J Clin Invest 1997;27:475-83. [Crossref] [PubMed]
  32. Leto D, Saltiel AR. Regulation of glucose transport by insulin: traffic control of GLUT4. Nat Rev Mol Cell Biol 2012;13:383-96. [Crossref] [PubMed]
  33. Viglianti BL, Wale DJ, Wong KK, Johnson TD, Ky C, Frey KA, Gross MD. Effects of Tumor Burden on Reference Tissue Standardized Uptake for PET Imaging: Modification of PERCIST Criteria. Radiology 2018;287:993-1002. [Crossref] [PubMed]
Cite this article as: Yang P, Fan Q, Cai H, Tian R, Su M. The effect of hypothyroidism on referential background metabolic activity on 18F-FDG PET/CT. Quant Imaging Med Surg 2021;11(8):3666-3676. doi: 10.21037/qims-20-1310